0000912282-17-000044.txt : 20170213 0000912282-17-000044.hdr.sgml : 20170213 20170213141508 ACCESSION NUMBER: 0000912282-17-000044 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20170213 DATE AS OF CHANGE: 20170213 GROUP MEMBERS: PUBLIC JOINT STOCK CO PHARMSTANDARD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-89601 FILM NUMBER: 17598087 BUSINESS ADDRESS: STREET 1: 521 COTTONWOOD DRIVE, SUITE 100 CITY: MALPITAS STATE: CA ZIP: 95035-7404 BUSINESS PHONE: 408-649-7370 MAIL ADDRESS: STREET 1: 521 COTTONWOOD DRIVE, SUITE 100 CITY: MALPITAS STATE: CA ZIP: 95035-7404 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Pharmstandard International S.A. CENTRAL INDEX KEY: 0001598762 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 65 BOULEVARD GRANDE DUCHESSE CHARLOTTE CITY: LUXEMBOURG STATE: N4 ZIP: L-1528 BUSINESS PHONE: 352 26449 557 MAIL ADDRESS: STREET 1: 65 BOULEVARD GRANDE DUCHESSE CHARLOTTE CITY: LUXEMBOURG STATE: N4 ZIP: L-1528 SC 13G 1 pharm-protag13g_021017.htm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

SCHEDULE 13G


INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Protagonist Therapeutics, Inc.
(Name of Issuer)



COMMON STOCK, $.00001 par value per share
(Title of Class of Securities)



74366E102
(CUSIP Number)


December 31, 2016
(Date of Event Which Requires Filing of This Statement)


Check the Appropriate box to designate the rule pursuant to which this schedule is filed:
 
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)


CUSIP No. 74366E102
13G
Page 2 of 9 Pages
 
 
1
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
  
 
Pharmstandard International S.A.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)  ☐
(b)  ☐
 
     
3
SEC USE ONLY
 
     
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Luxembourg
 
5
SOLE VOTING POWER
NUMBER OF
  
0
SHARES
6
SHARED VOTING POWER
BENEFICIALLY
  
983,570
OWNED BY
7
SOLE DISPOSITIVE POWER
EACH
  
0
REPORTING
8
SHARED DISPOSITIVE POWER
PERSON WITH
  
983,570
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
983,570
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ☐
 
     
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
5.88%*
 *Based on 16,714,453 shares of the Issuer’s common stock outstanding as of October 31, 2016, as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016.
12
TYPE OF REPORTING PERSON*
 
CO

CUSIP No. 74366E102
13G
Page 3 of 9 Pages

 
1
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
  
 
Public Joint Stock Company “Pharmstandard”
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)  ☐
(b)  ☐
 
 
     
3
SEC USE ONLY
 
     
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Russian Federation
 
5
SOLE VOTING POWER
NUMBER OF
  
0
SHARES
6
SHARED VOTING POWER
BENEFICIALLY
  
983,570
OWNED BY
7
SOLE DISPOSITIVE POWER
EACH
  
0
REPORTING
8
SHARED DISPOSITIVE POWER
PERSON WITH
  
983,570
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
983,570
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ☐
 
     
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
5.884%*
 *Based on 16,714,453 shares of the Issuer’s common stock outstanding as of October 31, 2016, as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016.
12
TYPE OF REPORTING PERSON*
 
HC
 
 
CUSIP No. 74366E102
13G
Page 4 of 9 Pages
 
Item 1 (a). Name of Issuer:

Protagonist Therapeutics, Inc.

Item 1 (b). Address of Issuer’s Principal Executive Offices:

521 Cottonwood Drive, Suite 100
Milpitas, California  95035

Item 2 (a). Name of Person(s) Filing:

Pharmstandard International S.A. (“Pharmstandard International”)

Public Joint Stock Company “Pharmstandard” (“Pharmstandard”)

Attached as Exhibit 99.1 is a copy of the Joint Filing Agreement between the reporting persons, pursuant to which they agree that this Schedule 13G is filed on behalf of each of them.

Item 2 (b). Address of Principal Business Office or, if None, Residence:

Principal business office for Pharmstandard International:
10a, rue Henri Schnadt
Luxembourg, N4 L-2530

Principal business office for Pharmstandard:
Likhachevsky proezd 5 “B”, Moscow region,
Dogoprudny town, Russian Federation  141700
 
Item 2 (c). Citizenship:

Pharmstandard International is a Luxembourg societe anonyme
Pharmstandard is a Russian public joint stock company

Item 2 (d). Title of Class of Securities:

Common Stock, $0.00001 par value per share.

Item 2 (e). CUSIP Number:

74366E102

Item 3.
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

(a)  ☐ Broker or dealer registered under Section 15 of the Act;
 
(b)  ☐
Bank as defined in Section 3(a)(6) of the Act;
 
(c)  ☐
Insurance Company as defined in Section 3(a)(19) of the Act;
 
(d)  ☐
Investment Company registered under Section 8 of the Investment Company Act;
 
(e)  ☐
Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
 
CUSIP No. 74366E102
13G
Page 5 of 9 Pages
 
 
(f)  ☐
Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);
 
(g)  ☐
Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);
 
(h)  ☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
 
(i)  ☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;
 
(j)  ☐
Group, in accordance with Rule 13d-1(b)(1)(ii)(j).

☐
If this statement is filed pursuant to Rule 13d-1(c), check this box.
 
Item 4.
Ownership.
 
Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

 
  
Pharmstandard
 International
 
Pharmstandard
 
(a)   Amount beneficially owned:
  
 
983,570
(1) 
 
983,570
(1) 
(b)   Percent of class:
 
 
5.88
%(2) 
 
5.88
%(2) 
(c)   Number of shares as to which such person has:
  
            
(i)    Sole power to vote or to direct the vote:
  
            
(ii)   Shared power to vote or to direct the vote:
  
 
983,570
(1) 
 
983,570
(1) 
(iii)  Sole power to dispose or to direct the disposition
       of:
  
            
(iv) Shared power to dispose or to direct the
       disposition of:
  
 
983,570
(1) 
 
983,570
(1) 


(1)
As of the date hereof Pharmstandard, as parent of Pharmstandard International, holds directly or indirectly a majority interest in the outstanding equity securities of Pharmstandard International and may therefore be deemed to beneficially own the shares covered by this Schedule 13G.
 
(2)
Based on 16,714,453 shares of the Issuer’s common stock outstanding as of October 31, 2016, as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2016.


Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

Item 5.
Ownership of Five Percent or Less of a Class.

If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].


Item 6.
Ownership of More than Five Percent on Behalf of Another Person.

N/A
 
CUSIP No. 74366E102
13G
Page 6 of 9 Pages
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

N/A

Item 8.
Identification and Classification of Members of the Group.

N/A

Item 9.
Notice of Dissolution of Group.

N/A
 
Item 10.      Certification.

N/A

CUSIP No. 74366E102
13G
Page 7 of 9 Pages



SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



 
February 10, 2017
 
(Date)
   
   
 
PHARMSTANDARD INTERNATIONAL S.A.
 
 
 
By: /s/ Eriks Martinovskis                                     
       Name: Eriks Martinovskis
       Title:  Director
 
   
   
   
   
   
CUSIP No. 74366E102
13G
Page 8 of 9 Pages



SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



 
February 10, 2017
 
(Date)
   
   
 
PUBLIC JOINT STOCK COMPANY “PHARMSTANDARD”
 
By: /s/ Chupikov Vladimir M.                                       
       Name: Chupikov Vladimir M.
       Title:  Chief Operating Officer
 
   
   
   
   

   
   

EX-99.1 2 ex99_1.htm JOINT FILING AGREEMENT
CUSIP No. 74366E102
13G
Page 9 of 9 Pages
 
Exhibit 99.1

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G as to any of the undersigned upon such person giving written notice thereof to each of the other persons signatory hereto, at the principal office thereof.

Dated: February 10, 2017


PHARMSTANDARD INTERNATIONAL S.A.


By: /s/ Erik Martinovskis                                         
Name: Erik Martinovskis
Title:   Director


PUBLIC JOINT STOCK COMPANY
“PHARMSTANDARD”


By: /s/ Chupikov Vladimir M.                                  
Name: Chupikov Vladimir M.
Title:   Chief Operating Officer